🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

...first results of PEACE 1 finally published... authors.elsevier.com/c/1etg2V-4XHC-…

A very interesting read from our collaborators on liquid biopsy testing in prostate cancer: PCF select is a panel to watch! #prostatecancer steven joniau Molendo

Congrats Diogo to a very interesting set of neoadjuvant treated PCa, nicely complementary to our ARNEO study. Excited to see your future work. Molendo steven joniau Gaëtan Devos

Excited for this intensive week designing a follow-up trial for the ARNEO study among many brilliant researchers! steven joniau EORTC

#ARNEO: a randomized phase II trial of neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk #ProstateCancer. Presentation by steven joniau UZ Leuven. #EAU22 written coverage by Zach Klaassen Georgia Cancer Center > bit.ly/3RjQqHl European Association of Urology (EAU)

Great opportunity for a trainee oncologist to join our team and become an expert on prostate cancer: atsv7.wcn.co.uk/search_engine/…

Excited to share our new work on clinical enzalutamide resistance and lineage plasticity (LP) in prostate cancer through the SU2C-PCF WCDreamTeam out now in Nature Communications! nature.com/articles/s4146… U-M Rogel Cancer Center, @UMichCancBio, UMich RNA Center 〽️🧬, PCF Science, @DRSNmoonshot

Very proud to present the ARNEO study published in European Urology!! In high-risk PCa patients, neoadjuvant degarelix plus apalutamide prior to RP results in significantly improved pathological response compared to degarelix alone! steven joniau A thread🧵👇: authors.elsevier.com/c/1fow714kplrK…

Proud on new paper from the Attard lab! Different novel insights in the PCa progression pathway.

Discover our work on the value of cystoscopy in bladder cancer detection, laying the basis for European and Canadian guidelines. Big team effort!

"Double trouble for prostate cancer: synergistic action of AR blockade and PARPi in non-HRR mutated patients" steven joniau Loïc Baekelandt Wout Devlies Gaëtan Devos Wouter Everaerts frontiersin.org/journals/oncol…

Happy to see our work highlighted during this #Movember month! Don't forget the impact of #androgendeprivation on #bone in #prostatecancer patients! bit.ly/3G3LKkd Great collaboration with our urology department Gaëtan Devos Wout Devlies steven joniau 👇👇👇

🔬 #PROpel unveiled PARP-inhibitors potential in #PCa, unveiling new potential synergies beyond HRRm! 🎯 More trials are needed for validation beyond pre-clinical data and pinpointing the ARSI + PARPi synergy in non-HRRm patients! steven joniau Wout Devlies authors.elsevier.com/a/1i9mm14kplvA…

Proud of our work from the Boston Lab on RT after neoadjuvant treatments in high-risk localized PCa: adjuvant RT rarely used and outcomes of both adjuvant and salvage poor. Patient selection will be key!

Amazing experience STEPS program! Nice Uroonco24. Thanks to the experts and colleagues!

European Association of Urology Guidelines on Urological Infections: Summary of the 2024 Guidelines by Jennifer Kranz et al. Full article: buff.ly/3XRiw2b Riccardo Bartoletti Rajan Veeratterapillay Kathrin Bausch Wout Devlies Lorenz Leitner Guglielmo Mantica Gernot Bonkat #Medtwitter #UroSoMe

Privileged seeing the ProBio published in Nature Medicine My sincerest gratitude for all the dedicated doctors, nurses, lab personnel, trial managers, and most importantly, the patients who made this possible🙏 Thank you @komop_tgkanker for making ProBio possible in🇧🇪

Out now: joint analysis of single cell and spatial transcriptomic data from 120 patients. Proud of this team effort!